rimactan hart hylki 300 mg
sandoz gmbh* - rifampicinum inn - hart hylki - 300 mg
rimactan hart hylki 150 mg
sandoz gmbh* - rifampicinum inn - hart hylki - 150 mg
risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 50 mg
teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 50 mg
paclitaxel actavis innrennslisþykkni, lausn 6 mg/ml
actavis group ptc ehf. - paclitaxelum inn - innrennslisþykkni, lausn - 6 mg/ml
marbodin filmuhúðuð tafla 10 mg
stada arzneimittel ag - memantinum hýdróklóríð - filmuhúðuð tafla - 10 mg
marbodin filmuhúðuð tafla 20 mg
stada arzneimittel ag - memantinum hýdróklóríð - filmuhúðuð tafla - 20 mg
risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 25 mg
teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg
risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 37,5 mg
teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg
vidaza
bristol-myers squibb pharma eeig - azasitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - Æxlishemjandi lyf - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
onureg
bristol-myers squibb pharma eeig - azasitidín - kyrningahvítblæði, mergbólga, bráð - Æxlishemjandi lyf - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).